

Resource Summary Report

Generated by [dkNET](#) on Sep 14, 2026

DV-90

RRID:CVCL_1184

Type: Cell Line

Proper Citation

RRID:CVCL_1184

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1184

Proper Citation: RRID:CVCL_1184

Description: Cell line DV-90 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung adenocarcinoma

Defining Citation: [PMID:7839470](#), [PMID:10908148](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26361996](#), [PMID:26589293](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#)

Comments: Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: DV-90

Synonyms: DV90

Cross References: CLO:CLO_0002847, EFO:EFO_0006565, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, BioSample:SAMN03473076, BioSample:SAMN10988133, cancercellines:CVCL_1184, Cell_Model_Passport:SIDM01510, ChEMBL-Cells:ChEMBL3308729, ChEMBL-Targets:ChEMBL1075437, Cosmic:753553, Cosmic:1146951, DepMap:ACH-000925, DSMZ:ACC-307, DSMZCellDive:ACC-307, EGA:EGAS00001000610, GDSC:753553, GEO:GSM434301, GEO:GSM784284, GEO:GSM886990, GEO:GSM888059, IARC_TP53:21313, IGRhCellID:DV-90_02GEO, LiGeA:CCLE_820, LINCS_LDP:LCL-

1636, PharmacDB:DV90_311_2019, PRIDE:PXD002556, Progenetix:CVCL_1184, PubChem_Cell_line:CVCL_1184, Wikidata:Q54831597

ID: CVCL_1184

Record Creation Time: 20220427T215825+0000

Record Last Update: 20260913T003024+0000

Ratings and Alerts

No rating or validation information has been found for DV-90.

No alerts have been found for DV-90.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Peck B, et al. (2021) 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer. Cancer research, 81(4), 847.

Alam H, et al. (2020) KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer. Cancer cell, 37(4), 599.

Sudhan DR, et al. (2020) Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers. Cancer cell, 37(2), 183.